Increased expression of vascular endothelial growth factor in cyclosporin A-induced gingival overgrowth in rats.
BACKGROUND
Gingival overgrowth is a side effect associated with cyclosporin A (CsA) therapy. The lesion is characterized by increased epithelial thickness, enlargement of connective tissue, and increased vascularization. The aim of this experimental study was to examine the role of vascular endothelial growth factor (VEGF) in the pathogenesis of CsA-induced gingival overgrowth.


METHODS
Twenty male Wistar rats were divided into two groups of 10 animals each. For the development of gingival overgrowth, one group received CsA therapy subcutaneously in a daily dose of 10 mg/kg for 60 days, and the other group was used as a control. At the end of the experimental period, rats were subsequently decapitated, and the mandibles with the surrounding gingiva and soft tissue were removed. Half of each sample was used for histomorphometric analysis, and the other half was used for biochemical analysis. Histomorphometric analysis included the measurements of the number and diameter of blood vessel profiles under a microscope, and biochemical analysis included the assessment of VEGF concentration by enzyme-linked immunosorbent assay (ELISA).


RESULTS
The histomorphometric findings showed that the number of blood vessel profiles increased in the CsA group compared to the control group (P <0.001), although the increase in the diameter of blood vessel profiles was not significant (P >0.05). The biochemical findings showed that in vivo VEGF expression was higher in the CsA group compared to the control group (P <0.001).


CONCLUSIONS
The results of this study suggest that increased VEGF expression may be associated with the pathogenesis of CsA-induced gingival overgrowth.
Cetinkaya
Burcu Ozkan
BO
Department of Periodontology, Faculty of Dentistry, Ondokuzmayis University, Samsun, Turkey. dtcetinkaya@yahoo.com
Acikgoz
Gokhan
G
Ayas
Bulent
B
Aliyev
Eldar
E
Sakallioglu
Elif Eser
EE
D000818:Animals; D001808:Blood Vessels / Q000187:drug effects / Q000473:pathology; D003238:Connective Tissue / Q000187:drug effects / Q000473:pathology; D016572:Cyclosporine / Q000009:adverse effects*; D004848:Epithelium / Q000187:drug effects / Q000473:pathology; D005881:Gingiva / Q000187:drug effects / Q000473:pathology; D019214:Gingival Overgrowth / Q000139:chemically induced / Q000473:pathology*; D007166:Immunosuppressive Agents / Q000009:adverse effects*; D008297:Male; D009389:Neovascularization, Pathologic / Q000139:chemically induced / Q000473:pathology; D011897:Random Allocation; D051381:Rats; D017208:Rats, Wistar; D042461:Vascular Endothelial Growth Factor A / Q000032:analysis*
D007166:Immunosuppressive Agents; D042461:Vascular Endothelial Growth Factor A; D016572:Cyclosporine